Mercury Pharmaceuticals

10

Dec 2025

Next-generation oral SERD therapy lowers the risk of breast cancer recurrence

In an international study led by UCLA, researchers have shown that giredestrant, a next-generation oral selective estrogen receptor antagonist and degrader (SERD), when given as an adjuvant therapy for early-stage (1-3) hormone receptor (HR)-positive, HER2-negative breast cancer, significantly lowered the risk of the disease returning when compared with standard hormone therapies long considered the backbone of treatment.

READ MORE

10

Dec 2025

Machine learning models can help diagnose ALS earlier from a blood sample

Using machine learning models, researchers at Michigan Medicine have identified a potential way to diagnose amyotrophic lateral sclerosis, or ALS, earlier from a blood sample, a study suggests.

READ MORE

10

Dec 2025

Triaptosis could be a promising strategy in the fight against cancer

Cancer remains one of the most critical global public health challenges, exerting profound social, economic, and clinical burdens while limiting gains in human life expectancy.

READ MORE

10

Dec 2025

Study shines new light on how cancer avoids the mitotic stopwatch pathway

When cell division (mitosis) takes too long, it can be a sign that something is wrong with the cells, for example DNA damage or chromosomal instability.

READ MORE

10

Dec 2025

MGI Tech empowers the University of Lisbon to study impact of Saharan dust on Portuguese agriculture with vineyards as key case study

MGI Tech partners with the University of Lisbon to monitor Saharan dust microorganisms, enhancing agricultural resilience and vineyard productivity in Portugal.

READ MORE

10

Dec 2025

Young adolescents participating in organized sports less likely to show oppositional-defiant behavior

Young adolescents, especially boys, who participated in organized sports between ages 6 and 10 are less likely to defy their parents, teachers and other authority figures, a new study by researchers in Canada and Italy suggests.

READ MORE

10

Dec 2025

Researchers map how brain networks differ in individuals at high clinical risk for psychosis

Researchers from the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), and NHG Health's Institute of Mental Health (IMH) have mapped how brain networks differ in individuals at Clinical High Risk (CHR) for psychosis, providing a new perspective on the mechanisms underlying the disease onset.

READ MORE

10

Dec 2025

EpilepsyGTx raises $33 million Series A to develop single dose gene therapy for focal refractory epilepsy

EpilepsyGTx, a biotechnology company focused on research and development of cutting-edge gene therapies to treat refractory epilepsy, today announced it has raised $33 million in a Series A financing to advance its lead program EPY201 through Phase 1/2a clinical trials.

READ MORE

10

Dec 2025

VALANX Biotech establishes Board of Directors

VALANX Biotech (VALANX), a biotech company developing novel antibody-drug-conjugate (ADC) assets enabled by its GoldenSite™ site-specific protein conjugation technology, today announced the formation of its Board of Directors.

READ MORE

10

Dec 2025

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

READ MORE